Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for Cardiovascular Health in COPD
NCT03819517Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Resveratrol with Placebo (2 arms). Primary endpoints: Change in Sirtuin 1 concentrations at 12 weeks, Change in vascular health at 12 weeks and 1 more. Started Jul 2019; status: completed.
02
Drugs
resveratrol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03819517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819517.